Appointment of Anilkumar Raghavan as CEO gets SPARC shareholders nod
New Delhi: Sun Pharma Advanced Research Company (SPARC) on Thursday said its shareholders have approved the appointment of Anilkumar Raghavan as chief executive officer.The company's shareholders have approved the "appointment of Anilkumar Raghavan as the manager and whole-time key managerial personnel of the company, designated as chief executive officer (CEO), for a term of 5 years...
New Delhi: Sun Pharma Advanced Research Company (SPARC) on Thursday said its shareholders have approved the appointment of Anilkumar Raghavan as chief executive officer.
The company's shareholders have approved the "appointment of Anilkumar Raghavan as the manager and whole-time key managerial personnel of the company, designated as chief executive officer (CEO), for a term of 5 years effective from May 25, 2021, up to May 24, 2026," SPARC said in a regulatory filing as quoted by PTI.
On the recommendation of the company's board of directors, the members at the annual general meeting (AGM) have approved an increase in the authorised share capital of the company from the current Rs 37.50 crore divided into 37,50,00,000 equity shares of Re 1 each to Rs 42.50 crore divided into 42,50,00,000 equity shares of Re 1 each, it added.
Mr. Anil Raghavan is the Chief Executive Officer of SPARC since April, 2014. In his role as CEO, Mr Raghavan sets SPARC's strategic priorities and focuses on developing the portfolio prudently and driving long-term stockholder value. Mr. Raghavan is a senior Pharmaceutical Services executive with significant global exposure spanning business strategy and operations.
Prior to joining SPARC in 2014, he served as the Managing Director of India and Sri Lanka business of Quintiles and has been an active member of their Asia Management Board.
Under his watch, Quintiles India maintained strong double-digit revenue and operating surplus growth in a turbulent business environment. He spent the first half of his career in the Consulting Industry with leading firms such as Arthur Andersen, KPMG and Cambridge Technology Partners. He helped the leadership teams of several companies in developing/evaluating strategies and improving business performance.
He has led/participated in several industry sector studies, working with business lobbies and industry associations to highlight sectoral opportunities and challenges.
Mr. Raghavan is an Industrial Engineer with a deep interest in evolving science and technologies enabling pharmaceutical R&D and health care. His other interests include the New Media, Digital Photography and Carnatic Music.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd